Enterprise Value

-4.645M

Cash

10.18M

Avg Qtr Burn

-7.964M

Short % of Float

8.44%

Insider Ownership

0.12%

Institutional Own.

8.12%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AVTX-803 (CERC-803) Details
Leukocyte Adhesion Deficiency Type II

Phase 3

Data readout

Phase 2

Update

Phase 2

Update

Phase 1b

Update

AVTX-007 (CERC-007) Details
Adult Onset Still's Disease

Phase 1b

Update

AVTX-006 (CERC-006) Details
Lymphatic malformations

Failed

Discontinued

AVTX-801 (CERC-801) Details
Metabolic disorder, Rare genetic disease

Failed

Discontinued

AVTX-802 (CERC-802) Details
Metabolic disorder, Rare genetic disease

Failed

Discontinued